Aurobindo Pharma gets USFDA’s nod for Azithromycin for Injection

22 Jun 2015 Evaluate

Aurobindo Pharma has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Azithromycin for Injection USP, 500mg /vial (ANDA 203294).

Azithromycin for Injection USP, 500mg /vial is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Zithromax (Azithromycin for Injection) 500mg/vial of Pfizer, Inc. Azithromycin for injection, USP is a macrolide antibacterial drug indicated for the treatment of patients with infections caused by susceptible strains of the designated microorganisms in the conditions such as Community-Acquired Pneumonia and Pelvic Inflammatory Disease.

Aurobindo now has 12 ANDAs (represented by 9 product classes) approved out of Unit IV formulation facility in Hyderabad, India for manufacturing general injectable products and will be marketed and sold by Aurobindo's wholly owned subsidiary AuroMedics Pharma LLC.

Aurobindo Pharma Share Price

1178.20 -7.30 (-0.62%)
16-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.80
Dr. Reddys Lab 1279.00
Cipla 1500.00
Zydus Lifesciences 913.90
Lupin 2089.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×